Insys Therapeutics Inc. (NASDAQ:INSY) shares rose 14.3% on Wednesday . The stock traded as high as $17.75 and last traded at $17.38, with a volume of 1,524,786 shares. The stock had previously closed at $15.20.

INSY has been the topic of several research reports. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, April 12th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $28.00 target price on shares of Insys Therapeutics in a research report on Wednesday, July 6th. Zacks Investment Research raised Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, June 29th. Jefferies Group increased their target price on Insys Therapeutics from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $32.00 target price (down from $44.00) on shares of Insys Therapeutics in a research report on Tuesday, April 12th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $24.67.

The company’s 50-day moving average is $14.54 and its 200-day moving average is $15.86. The company has a market cap of $1.24 billion and a P/E ratio of 25.00.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.01. During the same quarter in the prior year, the company earned $0.21 earnings per share. The business earned $67.10 million during the quarter, compared to the consensus estimate of $66.90 million. The business’s quarterly revenue was down 13.6% compared to the same quarter last year. On average, equities research analysts anticipate that Insys Therapeutics Inc. will post $0.36 EPS for the current fiscal year.

In other news, major shareholder John N. Kapoor Trust Dated Sept acquired 50,000 shares of the stock in a transaction on Thursday, May 12th. The shares were purchased at an average cost of $12.84 per share, for a total transaction of $642,000.00. Following the transaction, the insider now owns 31,982 shares in the company, valued at approximately $410,648.88. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Theodore H. Stanley sold 16,000 shares of Insys Therapeutics stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $16.27, for a total transaction of $260,320.00. Following the transaction, the director now owns 18,000 shares in the company, valued at $292,860. The disclosure for this sale can be found here.

Other institutional investors recently bought and sold shares of the company. California State Teachers Retirement System boosted its position in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after buying an additional 754 shares in the last quarter. Bank of Montreal Can boosted its position in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock valued at $1,909,000 after buying an additional 5,733 shares in the last quarter. Globeflex Capital L P boosted its position in Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock valued at $1,135,000 after buying an additional 39,600 shares in the last quarter. Airain ltd bought a new position in Insys Therapeutics during the fourth quarter valued at approximately $1,309,000. Finally, California Public Employees Retirement System boosted its position in Insys Therapeutics by 178.7% in the fourth quarter. California Public Employees Retirement System now owns 97,000 shares of the specialty pharmaceutical company’s stock valued at $2,777,000 after buying an additional 62,200 shares in the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.